Lekarstvennye preparaty dlya lecheniya legochnoy gipertenzii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents review dedicated to the pharmacotherapy of pulmonary hypertension (PH), resulting from a progressive increase in pulmonary vascular resistance and leading to right ventricular failure and premature death. Based on the results of numerous clinical studies, the efficacy and safety of drugs that are used as the primary and maintenance therapy of PH are analyzed. Maintenance pharmacotherapy includes the use of anticoagulants, cardiac glycosides and diuretics. Specific therapy of PH includes calcium channel blockers, prostacyclin analogues, endothelin receptor inhibitors and phosphodiesterase-5 (PDE-5) inhibitors.

Full Text

Restricted Access

References

  1. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American. Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol. 2009 Apr 28;53( 17):1573-619.
  2. McLaughlin V.V. Classification and epidemiology of pulmonary hypertension. J Am Coll Cardiol 2004;43( 12):5S-12S.
  3. Thenappan T., Shah S.J., Rich S., et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006 Eur Respir J 2007;30:1103-10.
  4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-49.
  5. Appelbaum L., Yigla M., Bendayan D., et al. Primary pulmonary hypertension in Israel: a national survey. Chest 2001;119(6): 1801 -806.
  6. Sandoval J., Bauerle O., Palomar A., et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994;89(4):1733-44.
  7. Shapiro S., Traiger G.L., Turner M., et al. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 2012; 141(2):363-73.
  8. McLaughlin VV., Davis M., Cornwell W. Pulmonary arterial hypertension. Curr Probl Cardiol 2011;36(12):461-517.
  9. Frumkin L.R. The Pharmacological Treatment of Pulmonary Arterial Hypertension. Pharmacol Rev 2012;1 [Epub ahead of print].
  10. Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А., Беленков Ю.Н. Легочная артериальная гипертензия: изменяющиеся подходы к лечению // Кардиология 2011. № 51(1). С. 100-8.
  11. Nerve P., Humbert M., Sitbon O., et al. Pathobiology of pulmonary hypertension: the role of plateletsand thrombosis. Clin Chest Med 2001 ;22:451 -58.
  12. Hoeper M.M., Sosada M., Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998;12:1446-49.
  13. Beckmann R., Frank H., Kneussl M. et al. Fibrinogen,t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994;150:929-33.
  14. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation1984;70:580-87.
  15. Gali N,. Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 2009;30(20):2493-537.
  16. Kawut S.M., Horn E.M., Berekashvili K.K., et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Chest 2008; 134:139-45.
  17. Badesch D.B., Abman S.H., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-28.
  18. Чазова И.Е., Мартынюк. Т.В., Адееев С.Н. и др. Российские рекомендации по диагностике и лечению легочной гипертензии // Кардиоваскулярная терапия и профилактика 2007. № 6(6). Приложение 2.
  19. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92.
  20. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med В стадии разработки находятся препараты нескольких фармакологических классов - ингибиторы КЬо-киназы, стимуляторы растворимой гуанилатци-клазы (риоцигуат и др.), вазоакшвные полипептиды, ингибиторы транспортера серотонина, ингибиторы протеинтирозинкиназы (иматиниб), фактор роста сосудистого эндотелия и др. [34]. 1992;327:76-81.
  21. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
  22. Tonelli A.R., Alnuaimat H., Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104(4):481-96.
  23. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
  24. Montani D., Savale L., Natali D., et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31 ( 15): 1898-907.
  25. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
  26. Badesch D.B., McLaughlin VV., Delcroix M., et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12):56S-61S.
  27. Ivy D.D. Prostacyclin in the intensive care setting. Pediatr Crit Care Med 2010; 11(2 Suppl.): S41-S5.
  28. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
  29. Sitbon O.H.M., Nunes H., Parent F., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-88.
  30. Chen Y.F., Jowett S., Barton P., et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health TechnolAssess 2009;13(49):1-320.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies